Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2,
administered orally to patients with advanced or refractory solid tumours, with MET
aberrations, and no available, approved therapeutic alternative.